Los puntos clave no están disponibles para este artículo en este momento.
PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis. (Current Controlled Trials number, ISRCTN49127736.)
Schröder et al. (Wed,) studied this question.